<p>In the United Kingdom, a top children's doctor has issued a warning over the delay in a new vaccine to combat respiratory syncytial virus (RSV). claiming that the dire situation may lead to more babies and infants in need of hospital treatment this winter.&nbsp;</p>

<p>Dr Camilla Kingdon, who is the president of the Royal College of Paediatrics and Child Health (RCPCH), told The Independent that she is frustrated as an RSV vaccine for babies has not yet been rolled out.&nbsp;</p>

<p>Dr Kingdon said: "We are frustrated [because] if we had acted sooner, we might have at least reduced the extent of the impact this winter and we have missed an opportunity there."&nbsp;</p>

<p><strong>Also read:&nbsp;<a href="https://www.wionews.com/world/japan-may-seek-court-order-to-dissolve-the-unification-church-632298">Japan may seek court order to dissolve the Unification church</a>&nbsp;</strong></p>

<p>"One of the aspects of winter that always fills us with dread is that we know that we will end up having to stop elective surgical lists because our hospitals are at full capacity with all the infections that we see in winter," she said.&nbsp;</p>

<p>"You've got to get ahead of the game. We are really disappointed that the programme hasn't been rolled out in a way that is going to make an impact for this winter, because we have been talking about this endlessly, but there's been a delay in activating the programme," she added.&nbsp;</p>

<p><strong>Watch:&nbsp;Labour reshuffle: Sir Keir Starmer to shake up shadow cabinet&nbsp;</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/labour-reshuffle-sir-keir-starmer-to-shake-up-shadow-cabinet-632229/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<h2><strong>What is RSV?</strong>&nbsp;</h2>

<p>RSV, which is a common and contagious virus that causes infections of the respiratory tract, affects both children and adults. Approximately, it causes 30,000 hospital admissions each winter and leads to dozens of deaths.&nbsp;</p>

<p>A last year's government report stated that Public Health England (PHE) estimated that over 60 per cent of children have been infected by their first birthday, and over 80 per cent by two years of age. Notably, the antibodies that are developed after an infection in early childhood, do not prevent further RSV infections throughout life.&nbsp;</p>

<p><strong>Also read:&nbsp;<a href="https://www.wionews.com/world/texas-drought-unveils-over-70-hidden-dinosaur-tracks-in-dry-paluxy-riverbed-632286">Texas drought unveils over 70 hidden dinosaur tracks in dry Paluxy riverbed</a>&nbsp;</strong>&nbsp;</p>

<p>RSV is a common cause of pneumonia but often causes cold-like symptoms. Since the virus was originally discovered in 1956, efforts to successfully manufacture a shot have been thwarted by the virus' complicated molecular structure and safety issues with earlier vaccine attempts.&nbsp;</p>

<p>Earlier this year in July, Britain's health regulator approved GSK's vaccine for RSV. The Medicines and Healthcare Products Regulatory Agency (MHRA) authorised GSK's shot, called Arexvy, for active immunisation to prevent lower respiratory tract disease caused by RSV in adults 60 years and older.&nbsp;</p>

<p>A Department of Health and Social Care spokesperson told The Independent: "The NHS already offers monoclonal antibodies which provide protection against RSV to infants at very high risk. We are developing plans for delivering wider infant and adult RSV programmes in collaboration with UKHSA, NHS England and manufacturers. We will update in due course."&nbsp;</p>

<p><strong>WATCH WION LIVE HERE</strong></p>

<p><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></p>

<p>You can <strong>now write for wionews.com</strong> and be a part of the community. Share your stories and opinions with us <strong><a href="https://www.wionews.com/content-contribution-registration-form">here</a>.</strong></p>


In the United Kingdom, a top children's doctor has issued a warning over the delay in a new vaccine to combat respiratory syncytial virus (RSV). claiming that the dire situation may lead to more babies and infants in need of hospital treatment this winter.

In the United Kingdom, a top children's doctor has issued a warning over the delay in a new vaccine to combat respiratory syncytial virus (RSV). claiming that the dire situation may lead to more babies and infants in need of hospital treatment this winter. Dr Camilla Kingdon, who is the president of the Royal College of Paediatrics and Child Health (RCPCH), told The Independent that she is frustrated as an RSV vaccine for babies has not yet been rolled out. Dr Kingdon said: "We are frustrated [because] if we had acted sooner, we might have at least reduced the extent of the impact this winter and we have missed an opportunity there." Also read: Japan may seek court order to dissolve the Unification church "One of the aspects of winter that always fills us with dread is that we know that we will end up having to stop elective surgical lists because our hospitals are at full capacity with all the infections that we see in winter," she said. "You've got to get ahead of the game. We are really disappointed that the programme hasn't been rolled out in a way that is going to make an impact for this winter, because we have been talking about this endlessly, but there's been a delay in activating the programme," she added. Watch: Labour reshuffle: Sir Keir Starmer to shake up shadow cabinet × What is RSV? RSV, which is a common and contagious virus that causes infections of the respiratory tract, affects both children and adults. Approximately, it causes 30,000 hospital admissions each winter and leads to dozens of deaths. A last year's government report stated that Public Health England (PHE) estimated that over 60 per cent of children have been infected by their first birthday, and over 80 per cent by two years of age. Notably, the antibodies that are developed after an infection in early childhood, do not prevent further RSV infections throughout life. Also read: Texas drought unveils over 70 hidden dinosaur tracks in dry Paluxy riverbed RSV is a common cause of pneumonia but often causes cold-like symptoms. Since the virus was originally discovered in 1956, efforts to successfully manufacture a shot have been thwarted by the virus' complicated molecular structure and safety issues with earlier vaccine attempts. Earlier this year in July, Britain's health regulator approved GSK's vaccine for RSV. The Medicines and Healthcare Products Regulatory Agency (MHRA) authorised GSK's shot, called Arexvy, for active immunisation to prevent lower respiratory tract disease caused by RSV in adults 60 years and older. A Department of Health and Social Care spokesperson told The Independent: "The NHS already offers monoclonal antibodies which provide protection against RSV to infants at very high risk. We are developing plans for delivering wider infant and adult RSV programmes in collaboration with UKHSA, NHS England and manufacturers. We will update in due course." WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

RSV concern in UK: Top doctor 'frustrated' over vaccine delay for babies

<p>The US Food and Drug Administration (FDA) has granted approval for a groundbreaking vaccine, Abrysvo, for pregnant women to&nbsp;safeguard infants from birth up to 6 months of age against lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV), the federal health agency said in a press release.&nbsp;</p>

<p>Notably, this is the first vaccine of its kind. Earlier&nbsp;in May, the federal agency approved Abrysvo for the prevention of LRTD caused by RSV in individuals aged 60 years and older.</p>

<p>Director of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, said, “RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease, which can lead to hospitalisation".</p>

<p>Also Read | <a href="https://www.wionews.com/world/russian-air-defence-intercepts-and-downs-two-attack-drones-near-moscow-627704">Russian Air Defence intercepts and downs two 'attack drones' near Moscow</a></p>

<p>“This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease," he added.&nbsp;</p>

<h2><strong>What is RSV?&nbsp;</strong></h2>

<p>RSV, a highly contagious virus responsible for respiratory infections across all age groups, especially impacts infants, making them susceptible to severe respiratory illness requiring hospitalisation. The approval of Abrysvo offers a vital preventive measure for pregnant women to shield infants from the potentially life-threatening effects of RSV.</p>

<p>Also Read | <a href="https://www.wionews.com/world/north-korea-threatens-thermonuclear-war-over-camp-david-summit-and-us-south-korea-drills-627702">North Korea threatens 'thermonuclear war' over Camp David summit and US-South Korea drills</a></p>

<p>Abrysvo is intended for administration during the gestational age of 32 to 36 weeks and involves a single-dose injection into the muscle. However, it is noteworthy that pregnant women who were highly susceptible to preterm birth were generally kept out of Abrysvo's clinical studies, the FDA press release said.&nbsp;</p>

<h2>Abrysvo side-effects&nbsp;</h2>

<p>Certain side effects were noticed among pregnant women who received the vaccine. These included pain at the injection site, headache, muscle pain, and nausea. Additionally, a rare but significant hypertensive disorder, pre-eclampsia, occurred more frequently among those who received Abrysvo compared to the placebo.</p>

<p><strong>Watch | Beijing's fruit diplomacy turns sour as China bans imports of Taiwanese mangoes</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/beijings-fruit-diplomacy-turns-sour-as-china-bans-imports-of-taiwanese-mangoes-627688/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>FDA said in a press release, "In addition, although not commonly reported, a dangerous hypertensive disorder, known as pre-eclampsia, occurred in 1.8% of pregnant individuals who received Abrysvo compared to 1.4% of pregnant individuals who received placebo. In the safety studies, low birth weight and jaundice in infants occurred at a higher rate in the pregnant Abrysvo recipients compared to pregnant placebo recipients."&nbsp;</p>

<h2><strong>Results of the study&nbsp;</strong></h2>

<p>Within 90 days after birth, Abrysvo showcased an 81.8 per cent reduction in severe LRTD risk and a 69.4 per cent reduction within 180 days after birth. For pregnant individuals at 32 to 36 weeks gestational age, Abrysvo led to a 34.7 per cent reduction in LRTD risk and an impressive 91.1 per cent reduction in severe LRTD risk within 90 days after birth.</p>

<p>Looking at the 180-day mark, Abrysvo demonstrated a 57.3 per cent reduction in LRTD risk and a 76.5 per cent reduction in severe LRTD risk compared to the placebo.&nbsp;</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<p><strong>WATCH WION LIVE HERE</strong></p>

<p><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></p>

<p>You can <strong>now write for wionews.com</strong> and be a part of the community. Share your stories and opinions with us <strong><a href="https://www.wionews.com/content-contribution-registration-form">here</a>.</strong></p>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>&nbsp;</p>

<p>&nbsp;</p>


The US Food and Drug Administration (FDA) has granted approval for a groundbreaking vaccine, Abrysvo, for pregnant women to safeguard infants from birth up to 6 months of age against lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV), the federal health agency said in a press release.

The US Food and Drug Administration (FDA) has granted approval for a groundbreaking vaccine, Abrysvo, for pregnant women to safeguard infants from birth up to 6 months of age against lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV), the federal health agency said in a press release. Notably, this is the first vaccine of its kind. Earlier in May, the federal agency approved Abrysvo for the prevention of LRTD caused by RSV in individuals aged 60 years and older. Director of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, said, “RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease, which can lead to hospitalisation". Also Read | Russian Air Defence intercepts and downs two 'attack drones' near Moscow “This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease," he added. What is RSV? RSV, a highly contagious virus responsible for respiratory infections across all age groups, especially impacts infants, making them susceptible to severe respiratory illness requiring hospitalisation. The approval of Abrysvo offers a vital preventive measure for pregnant women to shield infants from the potentially life-threatening effects of RSV. Also Read | North Korea threatens 'thermonuclear war' over Camp David summit and US-South Korea drills Abrysvo is intended for administration during the gestational age of 32 to 36 weeks and involves a single-dose injection into the muscle. However, it is noteworthy that pregnant women who were highly susceptible to preterm birth were generally kept out of Abrysvo's clinical studies, the FDA press release said. Abrysvo side-effects Certain side effects were noticed among pregnant women who received the vaccine. These included pain at the injection site, headache, muscle pain, and nausea. Additionally, a rare but significant hypertensive disorder, pre-eclampsia, occurred more frequently among those who received Abrysvo compared to the placebo. Watch | Beijing's fruit diplomacy turns sour as China bans imports of Taiwanese mangoes × FDA said in a press release, "In addition, although not commonly reported, a dangerous hypertensive disorder, known as pre-eclampsia, occurred in 1.8% of pregnant individuals who received Abrysvo compared to 1.4% of pregnant individuals who received placebo. In the safety studies, low birth weight and jaundice in infants occurred at a higher rate in the pregnant Abrysvo recipients compared to pregnant placebo recipients." Results of the study Within 90 days after birth, Abrysvo showcased an 81.8 per cent reduction in severe LRTD risk and a 69.4 per cent reduction within 180 days after birth. For pregnant individuals at 32 to 36 weeks gestational age, Abrysvo led to a 34.7 per cent reduction in LRTD risk and an impressive 91.1 per cent reduction in severe LRTD risk within 90 days after birth. Looking at the 180-day mark, Abrysvo demonstrated a 57.3 per cent reduction in LRTD risk and a 76.5 per cent reduction in severe LRTD risk compared to the placebo. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here. ×

US: FDA approves first vaccine for pregnant women to safegaurd infants from RSV

<p>A US Food and Drug Administration panel on Wednesday recommended two vaccines one each by Pfizer and GSK (GlaxoSmithKline) for their use in the United States against preventing Respiratory Syncytial Virus Infection (RSV) illness.&nbsp;</p>

<p>The recommended vaccines have proven to be effective in preventing the respiratory syncytial virus. The statistics show that Pfizer has a 66.7 % effectiveness in preventing disease whereas GSK's vaccine has 82.6% effectiveness, reported Reuters.&nbsp;</p>

<p>The FDA decision was reached after many hours of deliberations over the vaccines' safety concerns and their effectiveness against RSV.&nbsp;</p>

<p>However, the approval for the use of the vaccines will only be done after a final call taken by the FDA advisory committee and after a discussion by an experts' panel, the decision on the FDA vaccine could be made by the month of May.&nbsp;</p>

<p>Also Read | <a href="https://www.wionews.com/world/us-senate-clears-bill-to-declassify-all-information-on-covid-19-origin-567633">US Senate clears bill to declassify all information on Covid-19 origin</a></p>

<h2><strong>What is RSV?&nbsp;</strong></h2>

<p>RSV is defined as a common respiratory virus that usually causes mild, cold-like symptoms, as per the Centers for Disease Control and Prevention (CDC).&nbsp;</p>

<p>Once contracted with the RSV virus, the majority of people recover in about a week or two weeks. But RSV can be serious, especially for infants and older adults.&nbsp;</p>

<p>In fact, RSV is the most common cause of bronchiolitis and pneumonia in US children less than one year of age.&nbsp;</p>

<h2><strong>What are RSV symptoms?</strong></h2>

<p>RSV-infected people show symptoms such as runny nose, decrease in appetite, coughing, sneezing, fever and wheezing.&nbsp;After the contraction of the virus, the symptoms typically start to show within 4 to 6 days and appear in stages and not all at once.&nbsp;</p>

<p>Also Read | <a href="https://www.wionews.com/technology/an-affordable-tesla-no-details-revealed-by-elon-musk-on-investors-day-567625">An affordable Tesla? No details revealed by Elon Musk on investors' day</a></p>

<p>In very young infants with RSV, the only symptoms may be irritability, decreased activity, and breathing difficulties.</p>

<h2><strong>What are the preventive measures for RSV?</strong></h2>

<p>Even as most RSV patients recover from the illness in a day or two, there are preventive measures that one can take.&nbsp;One can manage fever and pain with over-the-counter fever reducers and pain relievers, such as acetaminophen or ibuprofen. Never give aspirin to children, as per CDC recommendations.&nbsp;</p>

<p>To prevent illness, individuals must drink enough fluids. It is important for people with RSV infection to drink enough fluids to prevent dehydration or loss of body fluids.&nbsp;</p>

<p>Watch | <a href="https://www.wionews.com/videos/israeli-protesters-confront-benjamin-netanyahus-wife-outside-tel-aviv-hair-salon-567643">Israeli Protesters Confront Benjamin Netanyahu's Wife Outside Tel Aviv Hair Salon</a></p>

<p>However, one must always speak with their healthcare provider before giving their child nonprescription cold medicines as some of these medicines contain ingredients that are not good for children.&nbsp;</p>

<p>In the most severe cases, a person may require additional oxygen, or IV fluids, or intubation with mechanical ventilation (a machine to help a person breathe).&nbsp;</p>

<p><strong>WATCH WION LIVE HERE</strong></p>

<p><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1  width=&quot;100%&quot;"></iframe></p>

<p>You can <strong>now write for wionews.com</strong> and be a part of the community. Share your stories and opinions with us <strong><a href="https://www.wionews.com/content-contribution-registration-form">here</a>.</strong></p>


A US Food and Drug Administration panel on Wednesday recommended two vaccines one each by Pfizer and GSK (GlaxoSmithKline) for their use in the United States against preventing Respiratory Syncytial Virus Infection (RSV) illness.

A US Food and Drug Administration panel on Wednesday recommended two vaccines one each by Pfizer and GSK (GlaxoSmithKline) for their use in the United States against preventing Respiratory Syncytial Virus Infection (RSV) illness. The recommended vaccines have proven to be effective in preventing the respiratory syncytial virus. The statistics show that Pfizer has a 66.7 % effectiveness in preventing disease whereas GSK's vaccine has 82.6% effectiveness, reported Reuters. The FDA decision was reached after many hours of deliberations over the vaccines' safety concerns and their effectiveness against RSV. However, the approval for the use of the vaccines will only be done after a final call taken by the FDA advisory committee and after a discussion by an experts' panel, the decision on the FDA vaccine could be made by the month of May. Also Read | US Senate clears bill to declassify all information on Covid-19 origin What is RSV? RSV is defined as a common respiratory virus that usually causes mild, cold-like symptoms, as per the Centers for Disease Control and Prevention (CDC). Once contracted with the RSV virus, the majority of people recover in about a week or two weeks. But RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis and pneumonia in US children less than one year of age. What are RSV symptoms? RSV-infected people show symptoms such as runny nose, decrease in appetite, coughing, sneezing, fever and wheezing. After the contraction of the virus, the symptoms typically start to show within 4 to 6 days and appear in stages and not all at once. Also Read | An affordable Tesla? No details revealed by Elon Musk on investors' day In very young infants with RSV, the only symptoms may be irritability, decreased activity, and breathing difficulties. What are the preventive measures for RSV? Even as most RSV patients recover from the illness in a day or two, there are preventive measures that one can take. One can manage fever and pain with over-the-counter fever reducers and pain relievers, such as acetaminophen or ibuprofen. Never give aspirin to children, as per CDC recommendations. To prevent illness, individuals must drink enough fluids. It is important for people with RSV infection to drink enough fluids to prevent dehydration or loss of body fluids. Watch | Israeli Protesters Confront Benjamin Netanyahu's Wife Outside Tel Aviv Hair Salon However, one must always speak with their healthcare provider before giving their child nonprescription cold medicines as some of these medicines contain ingredients that are not good for children. In the most severe cases, a person may require additional oxygen, or IV fluids, or intubation with mechanical ventilation (a machine to help a person breathe). WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

FDA panel recommends Pfizer, GSK vaccines against RSV for older adults, what is RSV, symptoms & prevention?

<p>Intensive care unit doctors in Germany said on Thursday that because of the rising cases of respiratory infections among infants, there is a massive strain on the hospital paediatric units across the nation.&nbsp;As per the intensive care association DIVI, the hospitals in the country are facing a "catastrophic situation" because of the surge in respiratory syncytial virus (RSV) cases, along with a shortage of nurses.&nbsp;</p>

<p>RSV is a common and contagious virus which causes infections of the respiratory tract. Medical experts have said that RSV is a negative-sense and single-stranded RNA virus. This virus infects nearly all babies and toddlers by age two, and some get seriously ill.&nbsp;</p>

<p><strong>ALSO READ |&nbsp;<a href="https://www.wionews.com/world/canada-summons-beijings-ambassador-issues-warning-over-alleged-chinese-police-stations-539360">Canada summons Beijing’s ambassador, issues warning over alleged Chinese police stations</a>&nbsp;</strong></p>

<p>As reported by The Association Press, experts have said that because of the relaxation in the coronavirus pandemic restrictions, RSV is currently affecting a larger number of babies and children.</p>

<p>The reports also mentioned that doctors are even making really tough and harsh decisions of selecting children as per their conditions to assign to limited intensive care beds.</p>

<p>There have been some cases where kids with RSV or maybe some other serious conditions are getting transferred to hospitals elsewhere in Germany with spare capacity.&nbsp;</p>

<p><strong>ALSO READ |&nbsp;<a href="https://www.wionews.com/world/emmanuel-macron-calls-for-us-france-to-be-brothers-in-arms-during-white-house-visit-539216">Macron, Biden pledge to hold Russia accountable for committing 'war crimes' in Ukraine</a>&nbsp;</strong></p>

<p>Citing a recent survey, the intensive care association also noted that there are fewer than 100 free paediatric beds nationwide and that the situation could worsen.&nbsp;</p>

<p>Sebastian Brenner, head of the paediatric intensive care unit at University Hospital Dresden, told German news channel n-tv: "If the forecasts are right, then things will get significantly more acute in the coming days and week. We see this in France, for example, and in Switzerland. If that happens, then there will be bottlenecks when it comes to treatment."&nbsp;</p>

<p>As quoted by the AP report, Dr Michael Sasse, head of paediatric intensive care at Hannover’s MHH University Hospital, said: "The situation is so precarious that we genuinely have to say children are dying because we can’t treat them anymore."&nbsp;</p>

<p><strong>WATCH WION LIVE HERE</strong></p>

<p><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></p>

<p>You can <strong>now write for wionews.com</strong> and be a part of the community. Share your stories and opinions with us <strong><a href="https://www.wionews.com/content-contribution-registration-form">here</a>.</strong></p>


Intensive care unit doctors in Germany said on Thursday that because of the rising cases of respiratory infections among infants, there is a massive strain on the hospital paediatric units across the nation.

Intensive care unit doctors in Germany said on Thursday that because of the rising cases of respiratory infections among infants, there is a massive strain on the hospital paediatric units across the nation. As per the intensive care association DIVI, the hospitals in the country are facing a "catastrophic situation" because of the surge in respiratory syncytial virus (RSV) cases, along with a shortage of nurses. RSV is a common and contagious virus which causes infections of the respiratory tract. Medical experts have said that RSV is a negative-sense and single-stranded RNA virus. This virus infects nearly all babies and toddlers by age two, and some get seriously ill. ALSO READ | Canada summons Beijing’s ambassador, issues warning over alleged Chinese police stations As reported by The Association Press, experts have said that because of the relaxation in the coronavirus pandemic restrictions, RSV is currently affecting a larger number of babies and children. The reports also mentioned that doctors are even making really tough and harsh decisions of selecting children as per their conditions to assign to limited intensive care beds. There have been some cases where kids with RSV or maybe some other serious conditions are getting transferred to hospitals elsewhere in Germany with spare capacity. ALSO READ | Macron, Biden pledge to hold Russia accountable for committing 'war crimes' in Ukraine Citing a recent survey, the intensive care association also noted that there are fewer than 100 free paediatric beds nationwide and that the situation could worsen. Sebastian Brenner, head of the paediatric intensive care unit at University Hospital Dresden, told German news channel n-tv: "If the forecasts are right, then things will get significantly more acute in the coming days and week. We see this in France, for example, and in Switzerland. If that happens, then there will be bottlenecks when it comes to treatment." As quoted by the AP report, Dr Michael Sasse, head of paediatric intensive care at Hannover’s MHH University Hospital, said: "The situation is so precarious that we genuinely have to say children are dying because we can’t treat them anymore." WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

'Catastrophic situation': ICU doctors in Germany alarmed over RSV cases’ spike, paediatric bed shortage

rsv-cases

Rsv Cases, News on Rsv Cases, stories on Rsv Cases, articles on Rsv Cases, Rsv Cases stories at Wion, Rsv Cases news, Rsv Cases latest news

rsv cases

RSV concern in UK: Top doctor 'frustrated' over vaccine delay for babies

US: FDA approves first vaccine for pregnant women to safegaurd infants from RSV

FDA panel recommends Pfizer, GSK vaccines against RSV for older adults, what is RSV, symptoms & prevention?

'Catastrophic situation': ICU doctors in Germany alarmed over RSV cases’ spike, paediatric bed shortage